Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized, Open-Label, 6-Period Cross-Over Study to Investigate the Dose Response of Dance 501 (Human Insulin Inhalation Solution and Inhaler) in Subjects With Type 2 Diabetes Mellitus (T2DM)

Trial Profile

A Randomized, Open-Label, 6-Period Cross-Over Study to Investigate the Dose Response of Dance 501 (Human Insulin Inhalation Solution and Inhaler) in Subjects With Type 2 Diabetes Mellitus (T2DM)

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 03 Oct 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Insulin (Primary) ; Insulin lispro
  • Indications Type 2 diabetes mellitus
  • Focus Pharmacodynamics; Pharmacokinetics
  • Acronyms Samba 04
  • Sponsors Aerami Therapeutics; Dance Biopharm

Most Recent Events

  • 11 Nov 2019 According to an Aerami Therapeutics media release, findings from two clinical studies (SAMBA-03 and SAMBA-04) will be presented at the 19th Diabetes Technology Meeting taking place on November 14-16, 2019.
  • 19 Sep 2019 According to a Dance Biopharm media release, data from this trial were presented at the 55th Annual Meeting of the European Association for the Study of Diabetes on September 19, 2019, in Barcelona, Spain.
  • 19 Sep 2019 Results presented in the Dance Biopharm media release.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top